EXCLUSIVE R&D PROCESS
New abdominal wall formation from a biological implant is a multi-step mechanism. During this process, metalloproteinases (MMps) which are involved in physiological wound healing allows the implant integration. MMPs are proteolytic enzymes synthesized during non-pathologic extracellular matrix (ECM) remodelling in order to degrade specifically ECM molecules. They can also remodel biological implants to create a physiological abdominal wall. However, an abnormal high level of MMPs can induce an unwanted fast implant degradation. In addition, on sceptic sites, proteases are produced by bacteria that further degrade ECM molecules, interfering with the physiological implant integration. Thus, the MMPs level plays a crucial role in the integration of the implant. To address this issue, we are working with a scientific committee to develop next-generation biomaterials that will help to treat complex pathologies where tissue and cellular engineering could meet unsatisfied medical needs.
The Scientific Committee of Meccellis Biotech is composed exclusively of surgeons’ specialists involved in the orientation and monitoring of R & D programs present and future.
Meccellis Biotech has established a special partnership to achieve its R & D programs with expert companies in collagen and re-absorbable biopolymers and biomedical applications.